PMID- 24729302
OWN - NLM
STAT- MEDLINE
DCOM- 20150602
LR  - 20160303
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 136
IP  - 11
DP  - 2015 Jun 1
TI  - The potential role of HIF on tumour progression and dissemination.
PG  - 2491-503
LID - 10.1002/ijc.28889 [doi]
AB  - Cancer is the second cause of mortality worldwide, primarily owing to failure to 
      cure metastatic disease. The need to target the metastatic process to reduce 
      mortality is clear and research over the past decade has shown hypoxia-inducible 
      factor-1 (HIF-1) to be one of the promising targets. In order for metastatic 
      disease to be established, multiple steps need to be taken whereby the tumour 
      cells escape into the bloodstream and survive, disseminate and then establish at 
      a premetastatic niche. HIF-1 mediates hypoxia-induced proangiogenic factors such 
      as vascular endothelial growth factor (VEGF) and platelet-derived growth factor 
      (PDGF), which promote extravasation and chemotaxis. The migration of tumour cells 
      is mediated by loss of E-cadherin, which results in a more invasive phenotype; 
      dissemination of the tumour cells by increased vascular permeability and survival 
      in the bloodstream through resistance to apoptosis as well as adhesion at the 
      premetastatic niche are all controlled by factors under the influence of HIF-1. 
      The overexpression of HIF in many aggressive cancer types as well as its role in 
      the establishment of metastatic disease and treatment resistance demonstrate its 
      potential target in therapeutics. Taken together, the role of HIF-1 in cancer and 
      metastatic disease is clear and the need for better treatment targeting 
      metastases is paramount; more aggressive phenotypes with less response to 
      treatment are associated with HIF-1 expression. Our research has shown promise 
      but many questions still remain to be answered.
CI  - (c) 2014 UICC.
FAU - Unwith, Sandeep
AU  - Unwith S
AD  - Section of Anaesthetics, Pain Medicine and Intensive Care, Department of Surgery 
      and, Cancer, Faculty of Medicine, Imperial College London, Chelsea & Westminster 
      Hospital, London, United Kingdom.
FAU - Zhao, Hailin
AU  - Zhao H
FAU - Hennah, Lindsay
AU  - Hennah L
FAU - Ma, Daqing
AU  - Ma D
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20140429
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Hypoxia-Inducible Factor 1)
SB  - IM
MH  - Antineoplastic Agents/pharmacology
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Hypoxia-Inducible Factor 1/antagonists & inhibitors/*metabolism
MH  - Neoplasm Metastasis
MH  - Neoplasms/metabolism/*pathology
OTO - NOTNLM
OT  - HIF-1
OT  - cancer metastasis
OT  - cancer therapy
EDAT- 2014/04/15 06:00
MHDA- 2015/06/03 06:00
CRDT- 2014/04/15 06:00
PHST- 2013/11/08 00:00 [received]
PHST- 2014/03/07 00:00 [revised]
PHST- 2014/04/03 00:00 [accepted]
PHST- 2014/04/15 06:00 [entrez]
PHST- 2014/04/15 06:00 [pubmed]
PHST- 2015/06/03 06:00 [medline]
AID - 10.1002/ijc.28889 [doi]
PST - ppublish
SO  - Int J Cancer. 2015 Jun 1;136(11):2491-503. doi: 10.1002/ijc.28889. Epub 2014 Apr 
      29.